Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jeena Sikho LifecareNSE:JSLL -2.21%92 3-Year EBITDA Growth Rate is 94.40% as of Mar. 2026, which is 22% above its 10-year median of 77.40. GuruFocus rates NSE:JSLL with a GF Score™ of 92/100 and a GF Value™ of ₹779.21 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 529 Healthcare Providers & Services companies, Jeena Sikho Lifecare ranks better than 98.68% on this metric.
During the past 12 months, Jeena Sikho Lifecare's average EBITDA Per Share Growth Rate was 142.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 94.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 86.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Jeena Sikho Lifecare was 96.10% per year. The lowest was 22.40% per year. And the median was 77.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Jeena Sikho Lifecare 3-Year EBITDA Growth Rate Related Terms
NSE:JSLL vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Jeena Sikho Lifecare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeena Sikho Lifecare 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jeena Sikho Lifecare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Jeena Sikho Lifecare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 94.40% mean?
Jeena Sikho Lifecare (NSE:JSLL) has a 3-Year EBITDA Growth Rate of 94.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Jeena Sikho Lifecare and its competitors. This is 22% above median its historical median of 77.40. Over the past decade, Jeena Sikho Lifecare's 3-Year EBITDA Growth Rate has ranged from 22.40 to 96.10. According to the industry distribution chart, Jeena Sikho Lifecare ranks #7 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 1.3%.
Is Jeena Sikho Lifecare's 3-Year EBITDA Growth Rate too high?
Jeena Sikho Lifecare's current 3-Year EBITDA Growth Rate of 94.40% is 22% above median its 10-year median of 77.40. Over the past 10 years, this metric has ranged from a low of 22.40 to a high of 96.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Jeena Sikho Lifecare's value of 94.40% is 825.5% above this industry median. Based on the distribution chart, Jeena Sikho Lifecare ranks #7 out of 529 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Jeena Sikho Lifecare has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jeena Sikho Lifecare's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jeena Sikho Lifecare ranks #7 out of 529 companies for 3-Year EBITDA Growth Rate. This places Jeena Sikho Lifecare in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. Jeena Sikho Lifecare's value of 94.40% is 825.5% above this benchmark. Historically, Jeena Sikho Lifecare's own 3-Year EBITDA Growth Rate has ranged from 22.40 to 96.10 over the past decade. While the company's 10-year median is 77.40 vs. the industry median of 10.20, Jeena Sikho Lifecare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jeena Sikho Lifecare's current 3-Year EBITDA Growth Rate of 94.40% is 825.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Jeena Sikho Lifecare and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jeena Sikho Lifecare's current 3-Year EBITDA Growth Rate is 94.40%, which is 22% above median its own 10-year median of 77.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeena Sikho Lifecare stock overvalued right now?
Based on GuruFocus' analysis, Jeena Sikho Lifecare (NSE:JSLL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹779.21, compared to a current price of ₹567.65 — trading 27.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 94.40%, which is 22% above median its 10-year median of 77.40 and 825.5% above the Healthcare Providers & Services industry median of 10.20. Jeena Sikho Lifecare's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Jeena Sikho Lifecare (NSE:JSLL), the current 3-Year EBITDA Growth Rate is 94.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeena Sikho Lifecare (NSE:JSLL) Overvalued in 2026?
Based on GuruFocus' analysis, Jeena Sikho Lifecare stock appears to be undervalued.
The current stock price of ₹567.65 is trading 27.2% below its estimated GF Value™ of ₹779.21.
GuruFocus considers Jeena Sikho Lifecare to be Modestly Undervalued.
Key valuation signals for NSE:JSLL:
3-Year EBITDA Growth Rate: 94.40% (22% above median its 10-year median of 77.40)
GF Value™: ₹779.21 vs. price of ₹567.65 (27.2% below fair value)
Industry Position: 825.5% above the Healthcare Providers & Services median (#7 of 529)
No single metric tells the full story. See the NSE:JSLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeena Sikho Lifecare Ltd provides Ayurvedic healthcare products and services. The company operates only in one business segment which is Trading of Ayurvedic Medicines and providing Ayurvedic therapies. The company engages in conducting health check-up camps, and free yoga sessions to make people aware of health problems. It offers a wide range of Ayurvedic products such as Shuddhi 32 Herbs Tea, Shuddhi Addiction Free Kit, Shuddhi BP Package, Shuddhi Diabetes Care Package, and Shuddhi Divya Sanjeevani-Anti-Viral Package.
92GF Score
Get the complete analysis for NSE:JSLL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JSLL has been successfully added to your 
